Abstract
Hepatocellular carcinoma (HCC) is associated with a high mortality rate. For many years, sorafenib was the only, and frequently poorly tolerated systemic treatment option, which lead to the unreflected recurrent use of locoregional treatment modalities, such as transarterial chemoembolization (TACE). Based on recent positive phase III trial results, we now have three systemic therapeutic options available in the first and second line of treatment, respectively. This development enables us to design sequential treatments concepts for patients with advanced HCC. Beyond the assessment of tumor burden, the liver function of HCC patients needs to be closely monitored under therapy. High response rates, including complete remissions have been documented for immuno-oncology-based combination regimens in HCC patients. Already today, a median overall survival (mOS) above 20 months can been achieved through the sequential application of systemic therapies in phase II studies in patients with advanced HCC and preserved liver function. Local therapies will remain an integral component of HCC therapy. However, recent advancements will shift the focus towards systemic treatment concepts. The rigorous implementation of validated scoring syste...Continue Reading
References
Jun 7, 2002·Lancet·Josep M LlovetUNKNOWN Barcelona Liver Cancer Group
Jan 24, 2003·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Josep M Llovet, Jordi Bruix
Jun 21, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Abby B SiegelJonathan D Schwartz
Jan 14, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Melanie B ThomasJames Abbruzzese
Mar 8, 2013·Journal of Hepatology·Bruno SangroJesús Prieto
Sep 18, 2014·Oncology·Sadahisa OgasawaraOsamu Yokosuka
Dec 17, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Philip J JohnsonHidenori Toyoda
Jan 7, 2016·Liver Cancer·Tadaaki ArizumiMasatoshi Kudo
Jan 15, 2016·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Riccardo LencioniJean-Francois H Geschwind
Jan 27, 2017·British Journal of Cancer·Imam WakedPhilip J Johnson
Feb 9, 2017·Liver International : Official Journal of the International Association for the Study of the Liver·Alessandro CucchettiRita Golfieri
Apr 25, 2017·Lancet·Anthony B El-KhoueiryIgnacio Melero
Jun 19, 2017·Gastroenterology·Daniela SiaJosep M Llovet
Jun 27, 2017·The Lancet. Gastroenterology & Hepatology·Tim MeyerDaniel H Palmer
Apr 10, 2018·Journal of Hepatology·UNKNOWN European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu, UNKNOWN European Association for the Study of the Liver
Apr 29, 2018·Journal of Hepatology·Richard S FinnJordi Bruix
Oct 31, 2018·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·James J HardingGhassan K Abou-Alfa
Feb 5, 2019·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A VogelE Martinelli
Nov 8, 2019·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Guohong HanPhilip J Johnson
Dec 4, 2019·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Richard S FinnUNKNOWN KEYNOTE-240 investigators
Jan 29, 2020·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A VogelE Martinelli